MTNB · Matinas BioPharma Holdings, Inc.
0.20
USDUnlock stock Insights
Create a free account to unlock price targets, recommendations, and commentary.
Overview
Market Cap
US$2.89M
PE
0.00
EV/EBITDA
N/A
DIV Yield
0%
Payout Ratio
0%
MQV Rating
5Very Weak
As at 24/08/2026 12:00:00 AM
Price Chart
Description
- All-Companies
Key Fundamentals
EPS 3 yr Growth
-58.60%
EBITDA Margin
N/A
Operating Cashflow
-$7m
Free Cash Flow Return
-92.20%
ROIC
-144.20%
Interest Coverage
N/A
Quick Ratio
2.80
Performance
52 weeks range
Low 0.18 - 2.24
Trade Value (12mth)
US$121,659.00
1 week
-21.67%
1 month
-26.77%
YTD
-70.56%
1 year
-89.51%
All time high
199.50
Additional Data
Shares Outstanding (Fully Diluted)
6m
HALO Sector
Healthcare
Next Company Report Date
01-Apr-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
Health Scores
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Valuation
Value
Consensus
Yield
News & Announcements
| Date | Event |
25 August 26EDG | |
14 August 26EDG | |
14 August 26EDG | |
05 August 26EDG | |
30 July 26EDG |
Key Stakeholders
| Name | Title |
| Ari Kluger | Individual |
| Adam K. Stern | Individual |
| David E. Lazar | Individual |
| 111 Equity Group LLC | Private Company |
| Jerome D. Jabbour | Individual |
